Register Login

Cartesian Therapeutics Inc (RNAC)

(10% Negative) CARTESIAN THERAPEUTICS, INC. (RNAC) Announces Delay in instrumental Trials for autoimmune diseases Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review

Full text
Register to leave comments
  • News bot Oct. 30, 2025, 11:12 a.m.

    📋 CARTESIAN THERAPEUTICS, INC. (RNAC) - Clinical Trial Update

    Filing Date: 2025-10-30

    Accepted: 2025-10-30 07:10:44

    Event Type: Clinical Trial Update

    Event Details:

    Cartesian Therapeutics Inc (RNAC) Announces Clinical Trial Update Cartesian Therapeutics Inc (RNAC) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: instrumental, grateful
    • Diseases/Conditions: autoimmune diseases, advancing Descartes-08 to where it is today
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Cartesian Therapeutics, Inc.
    • Updated Timeline: October 30, 2025, October 29, 2025

    🔬 Clinical Development Pipeline (CARTESIAN THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo Drug OTHER Phase PHASE3 Myasthaenia Gravis ClinicalTrials.gov
    Decartes-08 BIOLOGICAL Phase PHASE3 Myasthaenia Gravis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Cartesian Therapeutics Inc
    • CIK: 0001453687
    • Ticker Symbol: RNAC
    • Period End Date: 2025-10-29
    • Document Type: 8-K

Search

News categories